|
|
|
|
Pharmacokinetics, Safety and Tolerability of Tenofovir exalidex (CMX157), a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects
|
|
|
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Tawesak Tanwandee, MD, Somruedee Chatsiricharoenkul, MD,
Pisit Tangkijvanich, MD, Satawat Thongsawat, MD, Wattana Sukeepaisarnjaroen, MD, Anchalee Avihigsanon, MD, Piyawat Komolmit, MD, and Teerha Piratvisuth, MD
|
|
|
|
|
|
|